• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Raltegravir

Product ID R0247
Cas No. 518048-05-0
Purity ≥99%
Product Unit SizeCostQuantityStock
1 mg $76.50 In stock
5 mg $129.50 In stock
10 mg $233.00 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Raltegravir is an antiviral compound that inhibits HIV integrase; it is clinically used to treat HIV infection. In pre-clinical models, raltegravir decreases infection rates by preventing insertion of HIV-1 DNA into the host genome.

Product Info

Cas No.

518048-05-0

Purity

≥99%

Formula

C20H21FN6O5

Formula Wt.

444.42

IUPAC Name

N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide

Synonym

MK-0518

Solubility

soluble in water, slightly soluble in methanol, very slightly soluble in ethanol and acetonitrile and insoluble in isopropanol. The solubility of raltegravir increases with increasing pH such that its solubility in water is approx. 71 mg/mL. Its pKa is 6.3

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

R0247 MSDS PDF

Info Sheet

R0247 Info Sheet PDF

Brochures

Antivirals Booklet

References

Taramasso L, Madeddu G, Ricci E, et al. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomed Pharmacother. 2015 Feb;69:233-6. PMID: 25661363.

Mouscadet JF, Tchertanov L. Raltegravir: molecular basis of its mechanism of action. Eur J Med Res. 2009 Nov 24;14 Suppl 3:5-16. PMID: 19959411.

Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9. PMID: 19231980.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only